Researchers call for a microbiome moonshot to tackle chronic disease
An international team of researchers, including Rutgers microbiologists, has outlined ten priorities in Nature Medicine for testing how the human ...
Tag: Immunotherapy
Dormant Until They Reach the Brain: Engineered CAR-T Cells Clear a Lethal Pediatric Tumor in Mice
UC San Francisco scientists engineered B-SYNC CAR-T cells that activate only in the brain and cleared diffuse midline glioma in ...
Two-pronged antibody depletes suppressive T cells and boosts antitumor immunity in mice
A new bispecific antibody targeting CCR8 and CD3 shrank breast, lung and colon tumors in mice and was well tolerated ...
CAR-NK Cells Move From Concept Toward Clinic as Review Maps Engineering Fixes
A new review synthesizes engineering strategies and early clinical findings for CAR-NK cell immunotherapy in blood cancers and solid tumors.
CAR-T Therapy for Brain Tumors Shows Early Promise and Persistent Barriers
A conference correspondence summarizing 12 clinical and translational abstracts on next-generation CAR-T therapy for malignant brain tumors, reporting early feasibility ...
Gut Microbe Butyrate Signature Flags Early Resistance to Immunotherapy in Lung Cancer
A combined gut microbiome score linking probiotic-associated bacteria and butyrate production capacity was associated with early resistance to anti-PD-1 therapy ...
Scientists Launch Global Push to Outmaneuver a Fungus That Kills More Than Half Its Victims
A new PLOS Pathogens review introduces the NIAID-funded MUCOR-ADVANCE consortium, which unites diagnostics, immunotherapy and pathogenesis research against mucormycosis, a ...
ROS-responsive nanoparticle pairs PARP inhibitor with DOT1L blocker to fire up antitumor immunity in ovarian cancer models
A ROS-responsive nanoparticle co-delivering a PARP inhibitor prodrug and a DOT1L inhibitor amplified DNA damage, activated cGAS-STING signaling and improved ...
Immunotherapy plus targeted drug shows promise in rare aggressive lung cancer
A phase 2 trial reports that camrelizumab plus famitinib produced tumor shrinkage in 42.9 percent of patients with advanced pulmonary ...
Newly identified soluble SIRPα ligand SERPINA3 dampens inflammation and shields tumors
Researchers report that SERPINA3 acts as a soluble SIRPα ligand that suppresses immune cells, easing inflammatory disease models while helping ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!